πŸ‡ΊπŸ‡Έ FDA

Intelligence Platform

Patents

Browse 837 pharma-relevant US patents (A61K/A61P) linked to tracked companies. Patent cliff and LOE intelligence for BD teams.

29,054 patents indexed
patent

US 12421317

Polynucleotides encoding anti-glucagon-like peptide 1 receptor (GLP1R) antagonist antibodi

REGENERON PHARMACEUTICALS, INC. Β· Granted Tue Sep 23 2025 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Sep 18 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12419963

Diels-Alder conjugation methods

REGENERON PHARMACEUTICALS, INC. Β· Granted Tue Sep 23 2025 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Sep 18 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12421512

CRISPR/Cas screening platform to identify genetic modifiers of tau seeding or aggregation

REGENERON PHARMACEUTICALS, INC. Β· Granted Tue Sep 23 2025 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Sep 18 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12421315

CLL-1 targeted immunotherapies

REGENERON PHARMACEUTICALS, INC. Β· Granted Tue Sep 23 2025 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Sep 18 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12415856

EGFR x CD28 multispecific antibodies

REGENERON PHARMACEUTICALS, INC. Β· Granted Tue Sep 16 2025 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Sep 11 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12410442

Compositions and methods for treating sensorineural hearing loss using otoferlin dual vect

REGENERON PHARMACEUTICALS, INC. Β· Granted Tue Sep 09 2025 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Sep 04 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12402611

Genetically modified mice and engraftment

REGENERON PHARMACEUTICALS, INC. Β· Granted Tue Sep 02 2025 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Aug 28 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12404505

Delivery of a gene-editing system with a single retroviral particle and methods of generat

REGENERON PHARMACEUTICALS, INC. Β· Granted Tue Sep 02 2025 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Aug 28 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12396444

Mouse comprising a humanized TRKB locus

REGENERON PHARMACEUTICALS, INC. Β· Granted Tue Aug 26 2025 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Aug 21 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12398212

Methods for treating or preventing asthma by administering an IL-4R antagonist

REGENERON PHARMACEUTICALS, INC. Β· Granted Tue Aug 26 2025 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Aug 21 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12397028

Adoptive cellular therapy

REGENERON PHARMACEUTICALS, INC. Β· Granted Tue Aug 26 2025 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Aug 21 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12396952

Tuning of release kinetics in hydrogels

REGENERON PHARMACEUTICALS, INC. Β· Granted Tue Aug 26 2025 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Aug 21 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12391753

Antigen binding molecule formats

REGENERON PHARMACEUTICALS, INC. Β· Granted Tue Aug 19 2025 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Aug 14 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12391920

Models of tauopathy

REGENERON PHARMACEUTICALS, INC. Β· Granted Tue Aug 19 2025 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Aug 14 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12391734

PD-1 homing endonuclease variants, compositions, and methods of use

REGENERON PHARMACEUTICALS, INC. Β· Granted Tue Aug 19 2025 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Aug 14 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12389889

Mouse having a humanized cluster of differentiation 47 gene

REGENERON PHARMACEUTICALS, INC. Β· Granted Tue Aug 19 2025 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Aug 14 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12377159

Steroids and protein-conjugates thereof

REGENERON PHARMACEUTICALS, INC. Β· Granted Tue Aug 05 2025 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jul 31 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12378557

Treatment of sepsis with PCSK9 and LDLR modulators

REGENERON PHARMACEUTICALS, INC. Β· Granted Tue Aug 05 2025 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jul 31 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12378258

Biologically active molecules, conjugates thereof, and therapeutic uses

REGENERON PHARMACEUTICALS, INC. Β· Granted Tue Aug 05 2025 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jul 31 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12370257

Materials and methods of treating MHC-I-opathy risk haplotypes

REGENERON PHARMACEUTICALS, INC. Β· Granted Tue Jul 29 2025 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jul 24 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12371503

Methods of treatment using a leptin receptor agonist antibody

REGENERON PHARMACEUTICALS, INC. Β· Granted Tue Jul 29 2025 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jul 24 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12365711

TGFΞ² signal convertor

REGENERON PHARMACEUTICALS, INC. Β· Granted Tue Jul 22 2025 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jul 17 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12350374

Fabrication of protein-encapsulating microgels

REGENERON PHARMACEUTICALS, INC. Β· Granted Tue Jul 08 2025 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jul 03 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12350318

Combination therapy to treat brain cancer

REGENERON PHARMACEUTICALS, INC. Β· Granted Tue Jul 08 2025 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jul 03 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted